Veledimex structure
|
Common Name | Veledimex | ||
---|---|---|---|---|
CAS Number | 1093130-72-3 | Molecular Weight | 438.60200 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C27H38N2O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of VeledimexVeledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5. |
Name | N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide |
---|---|
Synonym | More Synonyms |
Description | Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5. |
---|---|
Related Catalog | |
In Vivo | Veledimex generally has moderate to low oral bioavailability after a single oral administration in mice and monkeys (-56% in mice and up to 17.4% in cynomolgus monkeys) with mostly low plasma clearance (1399 and 1170 mL/h per kilogram in mice and monkeys, respectively), high volume of distribution (20271 and 9180 mL/h per kilogram in mice and monkeys, respectively), and long terminal half-lives (-10 hours in mice and -30 hours in monkeys) after intravenous administration[1]. Ad-RTS-mIL-12 + veledimex have demonstrated a dose-related increase in tumor IL-12 mRNA and IL-12 protein expression. Discontinuation of veledimex resulted in a return to baseline IL-12 mRNA and protein expression in numerous syngeneic mouse tumor models. Veledimex crosses the blood-brain-barrier in both naive and orthotopic GL-261 mice with increased brain tissue level of -6 fold observed in tumor bearing vs. normal mice. Ad-RTS-mIL-12 + veledimex demonstrate a dose-related increase in survival without significant adverse events[2]. |
References |
Molecular Formula | C27H38N2O3 |
---|---|
Molecular Weight | 438.60200 |
Exact Mass | 438.28800 |
PSA | 62.13000 |
LogP | 6.45120 |
Storage condition | 2-8℃ |
INXN-1001 |
Veledimex |
UNII-ASU841TV0X |